Increased olanzapine discontinuation and health care resource utilization following a medicaid policy change

Journal of Clinical Psychiatry

Volumn 72, Issue 6, 2011, Pages 787-794

  Signorovitch, James ^a   Birnbaum, Howard ^a   Ben Hamadi, Rym ^a   Yu, Andrew P ^a   Kidolezi, Yohanne ^a   Kelley, David ^a   Phillips, Glenn ^b   Lawson, Anthony ^b   Ball, Daniel E ^b  

^a ANALYSIS GROUP   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; BIPOLAR DISORDER; COHORT ANALYSIS; CONTROLLED STUDY; DRUG CLASSIFICATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAID; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE PAYMENT; SCHIZOPHRENIA; TREATMENT OUTCOME; UNITED STATES;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; COHORT STUDIES; FEMALE; FLORIDA; HEALTH CARE COSTS; HUMANS; LOGISTIC MODELS; MALE; MEDICAID; MENTAL HEALTH SERVICES; MIDDLE AGED; NEW JERSEY; PHYSICIAN'S PRACTICE PATTERNS; POLICY; SCHIZOPHRENIA; UNITED STATES;

EID: 79959579028     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05868yel     Document Type: Article

References (26)

1. Hartman M, Martin A, McDonnell P, et al; National Health Expenditure Accounts Team. National health spending in 2007: slower drug spending contributes to lowest rate of overall growth since 1998. Health Aff (Millwood). 2009;28(1):246-261.doi:10.137/hlthaf.28.1.246 PubMed
2. Polinski JM, Wang PS, Fischer MA. Medicaid's prior authorization program and access to atypical antipsychotic medications. Health Aff (Millwood). 2007;26(3):750-760.doi:10.137/hlthaf.26.3.750 PubMed
3. Kahn RS, Fleischhacker WW, Boter H, et al; EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085-1097.doi:10.1016/S0140-6736(08)60486-9 PubMed
4. Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.doi:10.1056/NEJMoa05168 PubMed
5. Rosenheck RA, Leslie DL, Sindelar J, et al; CATIE Study Investigators. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry. 2006;163(12):2080-2089.doi:10.176/api.ajp.163.12.2080 PubMed (Pubitemid 46114227)
6. Lehman AF, Goldman HH, Dixon LB, et al. Evidence-Based Mental Health Treatments and Services: Examples to Inform Public Policy. http://www.milbank. org/reports/2004lehman/2004lehman.html. Published June 2004. Accessed November 30, 2010.
7. Stroup TS, Lieberman JA, McEvoy JP, et al; CATIE Investigators. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006;163(4):611-622.doi:10.176/api.ajp. 163.4.61 PubMed (Pubitemid 44464570)
8. Ascher-Svanum H, Zhu B, Faries DE, et al. Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia. Patient Prefer Adherence. 2008;2:67-77.doi:10.2147/PA.S2940 PubMed
9. Huskamp HA. Managing psychotropic drug costs: will formularies work? Health Aff (Millwood). 2003;22(5):84-96.doi:10.137/hlthaf.2.5.84 PubMed
10. Ray WA, Daugherty JR, Meador KG. Effect of a mental health "carve-out" program on the continuity of antipsychotic therapy. N Engl J Med. 2003;348(19):1885-1894.doi:10.1056/NEJMsa020584 PubMed
11. Soumerai SB, McLaughlin TJ, Ross-Degnan D, et al. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med. 1994;331(10):650-655.doi:10.1056/NEJM19409083106 PubMed (Pubitemid 24276866)
12. Zeber JE, Grazier KL, Valenstein M, et al. Effect of a medication copayment increase in veterans with schizophrenia. Am J Manag Care. 2007;13(6, pt 2):335-346. PubMed
13. Zhang Y, Adams AS, Ross-Degnan D, et al. Effects of prior authorization on medication discontinuation among Medicaid beneficiaries with bipolar disorder. Psychiatr Serv. 2009;60(4):520-527.doi:10.176/api.ps.60.4.520 PubMed
14. Soumerai SB, Zhang F, Ross-Degnan D, et al. Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. Health Aff (Millwood). 2008;27(3):w185-w195.doi:10.137/hlthaf.27.3.w185 PubMed (Pubitemid 351770278)
15. Mueser KT, McGurk SR. Schizophrenia. Lancet. 2004;363(9426):2063-2072. doi:10.1016/S0140-6736(04)16458-1 PubMed
16. Law MR, Soumerai SB, Ross-Degnan D, et al. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry. 2008;69(1):47-53.doi:10.408/JCP.v69n0107 PubMed (Pubitemid 351281996)
17. Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55(8):886-891.doi:10.176/api.ps.5.8.86 PubMed (Pubitemid 39025215)
18. Zeber JE, Copeland LA, Miller AL, et al. A cost-benefit analysis of higher medication copayments in veterans with schizophrenia. In: Abstracts of the National Meeting of the Health Services Research & Development Service; February 11-13, 2009; Baltimore, MD. Abstract 1005.
19. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619. doi:10.1016/0895-4356(92)9013-8 PubMed
20. Angrist JD, Imbens GW. Two-stage least-squares estimation of average causal effects in models with variable treatment intensity. J Am Stat Assn. 1995;90(430):431-442.
21. Angrist JD, Imbens GW, Rubin DB. Identification of causal effects using instrumental variables. J Am Stat Assn. 1996;91(434):444-455. (Pubitemid 126412813)
22. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. London, UK: Chapman and Hall/CRC; 1993.
23. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892-909. PubMed
24. Ascher-Svanum H, Faries DE, Zhu B, et al. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006;67(3):453-460.doi:10.408/JCP.v67n0317 PubMed
25. Busch AB, Lehman AF, Goldman H, et al. Changes over time and disparities in schizophrenia treatment quality. Med Care. 2009;47(2):199-207. doi:10.1097/MLR.0b013e31818475b7 PubMed
26. Parks J, Radke A, Parker G, et al. Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment. Schizophr Bull. 2009;35(5):931-936.